Lexicon Genetics Initiates Clinical Trials Of LX1031 For Irritable Bowel Syndrome
Thu, 25 Jan 2007 08:00 AM EST
... Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has initiated Phase 1 clinical trials of LX1031, its oral drug candidate for irritable bowel syndrome (IBS) and other gastrointestinal disorders. [click link for full article] ...
Related Topics
- Irritable Bowel Syndrome
- Genetics & Genomics
- Genetics
- Irritable Bowel Syndrome in Children
- Clinical Trials
- What I need to know about Irritable Bowel Syndrome
- Irritable Bowel Syndrome Diet
- Inflammatory Bowel Disease
- Irritable Bowel
- Marfan Syndrome
- Short Bowel Syndrome
- Crohn's Disease
- Irbesartan
- Pharmacology
- Psychopharmacology
- Bowel and Intestines
- Syndrome X
- Asperger's Syndrome
- Down Syndrome
- Genomics & Disease Prevention

Not Signed In -


